Office of New Drugs (OND) | Annual Reports
2021 marked the second year the Office of New Drugs (OND) developed an Annual Report. The 2021 report captures the office’s major achievements working together with other CDER offices. It highlights OND’s commitment to scientific leadership in driving innovation in drug trial designs, progression in drug development, and collaboration throughout FDA and with external stakeholders.
- 2021 Office of New Drugs Annual Report (PDF - 8 MB)
- 2020 Office of New Drugs Annual Report (PDF - 18 MB)